[{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Oxalate","graph1":"Nephrology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ DCVC Bio"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Chinook Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"DM199","moa":"Kallikrein-1","graph1":"Nephrology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalent Pharma Solutions \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Not Applicable"},{"orgOrder":0,"company":"University of Rochester School of Medicine & Dentistry","sponsor":"Evgen Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"SFX-01","moa":"Nrf2","graph1":"Nephrology","graph2":"Undisclosed","graph3":"University of Rochester School of Medicine & Dentistry","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma","highestDevelopmentStatusID":"1","companyTruncated":"University of Rochester School of Medicine & Dentistry \/ Evgen Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Phase III","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","graph1":"Nephrology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Cowen Healthcare Investments","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Ilofotase alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.17999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Cowen Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Cowen Healthcare Investments"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MOR202","moa":"CD38","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Not Applicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Terlipressin Acetate","moa":"V1R\/V2R","graph1":"Nephrology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Galera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Nephrology","graph2":"Phase II","graph3":"Galera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Galera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Galera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CCX140","moa":"CCR2 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Terevalefim","moa":"c-Met","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"ProSciento","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nimacimab","moa":"CB1","graph1":"Nephrology","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Skye Bioscience \/ ProSciento","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ ProSciento"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napp Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Napp Pharmaceuticals \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Aduro Biotech"},{"orgOrder":0,"company":"Complexa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CXA-10","moa":"Nrf2","graph1":"Nephrology","graph2":"Phase II","graph3":"Complexa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Complexa \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Complexa \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Citigroup Global Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.080000000000000002,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Citigroup Global Markets","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Citigroup Global Markets"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.089999999999999997,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Jefferies LLC","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Jefferies LLC"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Jefferies"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Phase II","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kyowa Kirin \/ Ardelyx","highestDevelopmentStatusID":"8","companyTruncated":"Kyowa Kirin \/ Ardelyx"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Eventide Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Eventide Asset Management"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Napp Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"Napp Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Napp Pharmaceuticals \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Napp Pharmaceuticals \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Emcure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"Emcure Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emcure Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Millmount Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tolvaptan","moa":"V2R","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Millmount Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Millmount Healthcare"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mundipharma \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2020","type":"Public Offering","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.20000000000000001,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Shield Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferric oxide adipate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Shield Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shield Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shield Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Dimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Propagermanium","moa":"CCR2","graph1":"Nephrology","graph2":"Phase II","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dimerix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dimerix \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Private Placement","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Leo Pharma \/ Cheplapharm","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma \/ Cheplapharm"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Aduro Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Aduro Biotech"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Human gut microbiome","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Federation Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Federation Bio \/ Horizons Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Federation Bio \/ Horizons Ventures"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"suPAR","graph1":"Nephrology","graph2":"Discovery","graph3":"Walden Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Walden Biosciences \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Walden Biosciences \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase II","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apellis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Labcorp Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"KBP-5074","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Labcorp Drug Development","highestDevelopmentStatusID":"8","companyTruncated":"KBP Biosciences \/ Labcorp Drug Development"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ilofotase alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Fresenius Kabi","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Fresenius Kabi"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Metolazone","moa":"Sodium-chloride cotransporter","graph1":"Nephrology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Lanthanum Dioxycarbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Zukunftsfonds Heilbronn","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"CPV-101","moa":"Complement C3","graph1":"Nephrology","graph2":"Preclinical","graph3":"Elevar Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn","highestDevelopmentStatusID":"4","companyTruncated":"Elevar Therapeutics \/ Zukunftsfonds Heilbronn"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Radboud University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Radboud University Medical Center"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Abingworth LLP","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Series C Financing","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Abingworth LLP","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Abingworth LLP"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"BenevolentAI \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"BenevolentAI \/ AstraZeneca"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Chewable Tablet","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Amniotic fluid derived stem cells","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Creative Medical Technology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Creative Medical Technology \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Creative Medical Technology \/ Not Applicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"Tai Tien Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Mitsubishi Tanabe Pharma \/ Tai Tien Pharmaceutical"},{"orgOrder":0,"company":"Evotec","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Chinook Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Harvard University","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Kirin \/ Harvard University","highestDevelopmentStatusID":"2","companyTruncated":"Kyowa Kirin \/ Harvard University"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"TXR-1208","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"twoXAR Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"twoXAR Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"twoXAR Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Telara Pharma","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cilastatin","moa":"DPEP1","graph1":"Nephrology","graph2":"Preclinical","graph3":"Telara Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Telara Pharma \/ Arch Biopartners","highestDevelopmentStatusID":"4","companyTruncated":"Telara Pharma \/ Arch Biopartners"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"DiaMedica Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"DM199","moa":"Kallikrein-1","graph1":"Nephrology","graph2":"Phase II","graph3":"DiaMedica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"DiaMedica Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"DiaMedica Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.070000000000000007,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nephraegis Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"NPH-022","moa":"Epoxyeicosatrienoic acid","graph1":"Nephrology","graph2":"Preclinical","graph3":"Nephraegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Nephraegis Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"Nephraegis Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Belimumab","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"The American College of Cardiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"The American College of Cardiology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The American College of Cardiology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"The American College of Cardiology \/ Not Applicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ziltivekimab","moa":"Il-6","graph1":"Nephrology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Solnatide","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II","graph3":"Alebund Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Alebund Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alebund Pharmaceuticals \/ Quan Capital"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"GFB-024","moa":"CB1","graph1":"Nephrology","graph2":"Phase I","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Goldfinch Bio, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Enteris Biopharma Inc","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Enteris Biopharma Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Enteris Biopharma Inc \/ Cara Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Enteris Biopharma Inc \/ Cara Therapeutics"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Praliciguat","moa":"sGC","graph1":"Nephrology","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Cyclerion Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Tribune Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"CCN2","graph1":"Nephrology","graph2":"Preclinical","graph3":"Tribune Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Tribune Therapeutics \/ HEALTHCAPS INDIA LTD","highestDevelopmentStatusID":"4","companyTruncated":"Tribune Therapeutics \/ HEALTHCAPS INDIA LTD"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"AM-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Ilofotase Alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"KBI Biopharma \/ AM-Pharma","highestDevelopmentStatusID":"10","companyTruncated":"KBI Biopharma \/ AM-Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Reloxaliase","moa":"Oxalate","graph1":"Nephrology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Bayer AG","sponsor":"American Association of Kidney Patients","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ American Association of Kidney Patients","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ American Association of Kidney Patients"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ Not Applicable"},{"orgOrder":0,"company":"Aronora","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Xisomab 3G3","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Aronora","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Aronora \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aronora \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Not Applicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Constellation Alpha Holdings","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Merger","leadProduct":"Human Acellular Vessels","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.25,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Constellation Alpha Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Constellation Alpha Holdings"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Sinovent","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"XNW1011","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Sinovent","amount2":0.56000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.56000000000000005,"dosageForm":"Capsule","sponsorNew":"Sinovent \/ Everest","highestDevelopmentStatusID":"4","companyTruncated":"Sinovent \/ Everest"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.19,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ADX-097","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Q32 Bio \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ARO-C3","moa":"Complement C3","graph1":"Nephrology","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.16,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ SVB Leerink"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Deep Track Capital","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Deep Track Capital"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arthrosi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"AR882","moa":"URAT1","graph1":"Nephrology","graph2":"Phase I","graph3":"Arthrosi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Arthrosi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arthrosi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"BION-1301","moa":"APRIL","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"Factor B","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"ADX-097","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Not Applicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Rockwell Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"Transferrin","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Rockwell Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rockwell Medical \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Rockwell Medical \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"VX-147","moa":"ApoL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Delayed-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sevelamer Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder for Concentrate for Solution for Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"FrostPharma AB","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ FrostPharma AB","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ FrostPharma AB"},{"orgOrder":0,"company":"ProKidney","sponsor":"Social Capital Suvretta Holdings Corp. III","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProKidney \/ Social Capital Suvretta Holdings Corp. III","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Social Capital Suvretta Holdings Corp. III"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Belimumab","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Zhejiang Ausun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Repirinast","moa":"Mast cell","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Zhejiang Ausun Pharmaceutical"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BCX9930","moa":"Factor D","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCryst Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRCP5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"Phosphate","graph1":"Nephrology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Everest Medicines"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Acetate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AB Brunna \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Boehringer Ingelheim","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Boehringer Ingelheim"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Endothelin A receptor\/Angiotensin II subtype 1 receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet\n","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VX-147","moa":"ApoL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MTX652","moa":"USP30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Akebia Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"Nrf2","graph1":"Nephrology","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reata Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Komodo Health","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Komodo Health","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Komodo Health"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified-release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dipalmitoylphosphatidylglycerol","moa":"Apolipoprotein A-I","graph1":"Nephrology","graph2":"Phase II","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Abionyx Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Abionyx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ilofotase Alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.28999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"NHE3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Cara Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Otsuka"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ Not Applicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Delayed-release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"AT-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CLBS201","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BION-1301","moa":"BCMA receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Evotec","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Evotec"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Atrasentan","moa":"Endothelin receptor A","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.11,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"GFB-024","moa":"CB1","graph1":"Nephrology","graph2":"Phase I","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Goldfinch Bio, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","graph1":"Nephrology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Pharmaceuticals \/ Sobi"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Inaxaplin","moa":"APOL1","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pozelimab","moa":"C5 complement","graph1":"Nephrology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"HIF-PH","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":1.8999999999999999,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Ardelyx","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ADX-097","moa":"Complement activity","graph1":"Nephrology","graph2":"Phase I","graph3":"Q32 Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Q32 Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Q32 Bio \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"Saniona","sponsor":"University of Arhus","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ University of Arhus","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ University of Arhus"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TST004","moa":"MASP2","graph1":"Nephrology","graph2":"Preclinical","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ANG-3070","moa":"RTK","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Dual endothelin\/Angiotensin receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"suPAR","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"1","companyTruncated":"Walden Biosciences \/ University of Michigan"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BION-1301","moa":"BCMA receptor","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Goldfinch Bio, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"GFB-887","moa":"TRPC5","graph1":"Nephrology","graph2":"Phase II","graph3":"Goldfinch Bio, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Goldfinch Bio, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Goldfinch Bio, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Repirinast","moa":"Mast cell","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IONIS-FB-LRx","moa":"Complement factor B","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Roche","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Roche"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"2-hydroxypropyl-beta Cyclodextrin","moa":"Cholesterol efflux","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition Corp."},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fesomersen","moa":"Factor XI","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Bayer","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Bayer"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Belimumab","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CLBS201","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lisata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Lisata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NovelMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"NM8074","moa":"C3\/ C5 convertase","graph1":"Nephrology","graph2":"Phase I","graph3":"NovelMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"NovelMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NovelMed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vifor Fresenius Medical Care Renal Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Iron Sucrose","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Vifor Fresenius Medical Care Renal Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Vifor Fresenius Medical Care Renal Pharma \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Vifor Fresenius Medical Care Renal Pharma \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Medison Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"Immunoglobulin","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Medison Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Dual endothelin\/Angiotensin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSL \/ Travere Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Travere Therapeutics"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pozelimab","moa":"Completent C5","graph1":"Nephrology","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MK-2060","moa":"Factor XI","graph1":"Nephrology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dapagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD154","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"STADA Arzneimittel \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Calliditas Therapeutics"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Itolizumab","moa":"CD6","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Balixafortide","moa":"CXCR4","graph1":"Nephrology","graph2":"Phase I","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Spexis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Larkspur Health Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Larkspur Health Acquisition"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Oxypurinol","moa":"Xanthine oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TST004","moa":"MASP2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Series C Financing","leadProduct":"INV-202","moa":"Peripheral CB1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ New Enterprise Associates","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ New Enterprise Associates"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"EB003","moa":"STEC bacteria","graph1":"Nephrology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Eligo Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Dual endothelin\/Angiotensin receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"A2AR","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Not Applicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Felzartamab","moa":"CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0.12,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ ARCH Venture Partners","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.52000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.52000000000000002,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Kyowa Kirin","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Kyowa Kirin"},{"orgOrder":0,"company":"Tricida, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Veverimer","moa":"HCl","graph1":"Nephrology","graph2":"Phase III","graph3":"Tricida, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tricida, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tricida, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Eledon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Tegoprubart","moa":"CD40","graph1":"Nephrology","graph2":"Phase II","graph3":"Eledon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eledon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eledon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"TLR4","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"CinCor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baxdrostat","moa":"Aldosterone synthase","graph1":"Nephrology","graph2":"Phase II","graph3":"CinCor Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CinCor Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CinCor Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sparsentan","moa":"Angiotensin II type-1 receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"Mineralocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"Calcineurin","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Saniona \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ Not Applicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"Xanthine Oxidase","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ALPN-303","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Fesomersen","moa":"Factor XI","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"MZ-301","moa":"APOL1","graph1":"Nephrology","graph2":"Preclinical","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Maze Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Maze Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"IONIS-FB-LRx","moa":"Complement factor B","graph1":"Nephrology","graph2":"Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ionis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ionis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"KYV-101","moa":"CD19","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Everest Medicines \/ Calliditas","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INV-202","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Inversago Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Viatris","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Viatris"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"IGAN Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"IGAN Biosciences \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"IGAN Biosciences \/ Selecta Biosciences"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ZyVersa Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Unicycive Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lanthanum Carbonate","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Unicycive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Unicycive Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Unicycive Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bumetanide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Eli Lilly"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Orbsen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stromal Cell","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Orbsen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orbsen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Orbsen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Daprodustat","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Evotec","amount2":1,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":1,"dosageForm":"Oral","sponsorNew":"Evotec \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Eli Lilly"},{"orgOrder":0,"company":"MorphoSys","sponsor":"HIBio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Felzartamab","moa":"CD38","graph1":"Nephrology","graph2":"Phase II","graph3":"MorphoSys","amount2":1.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.02,"dosageForm":"Infusion","sponsorNew":"MorphoSys \/ HIBio","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ HIBio"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Canadian Institute of Health Resources","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Undisclosed","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Canadian Institute of Health Resources","highestDevelopmentStatusID":"1","companyTruncated":"Arch Biopartners \/ Canadian Institute of Health Resources"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"REVTx-300","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories International","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Charles River Laboratories International","highestDevelopmentStatusID":"4","companyTruncated":"Purespring Therapeutics \/ Charles River Laboratories International"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Disc medicine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ADX\u2011629","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Potassium Citrate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-Release Granule","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"12","companyTruncated":"Avanzanite Bioscience \/ Advicenne"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Jefferies","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Teijin Pharma","amount2":0.23000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Teijin Pharma \/ Novartis","highestDevelopmentStatusID":"4","companyTruncated":"Teijin Pharma \/ Novartis"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Oxypurinol","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Xortx Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xortx Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Empagliflozin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Inaxaplin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Guangdong Academy of Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Everest Medicines \/ Guangdong Academy of Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Everest Medicines \/ Guangdong Academy of Medical Sciences"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Humacyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Human Acellular Vessels","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Humacyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Humacyte \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Humacyte \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Drogsan Pharmaceuticals","sponsor":"Rockwell Medical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ferric Pyrophosphate Citrate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Drogsan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Drogsan Pharmaceuticals \/ Rockwell Medical","highestDevelopmentStatusID":"12","companyTruncated":"Drogsan Pharmaceuticals \/ Rockwell Medical"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Multiomic Health","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Multiomic Health","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0.01,"dosageForm":"","sponsorNew":"Multiomic Health \/ Hoxton Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Multiomic Health \/ Hoxton Ventures"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Reata Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bardoxolone Methyl","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kyowa Kirin \/ Reata Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Reata Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Chinook Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ionis Pharmaceuticals \/ Chinook Therapeutics"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Cara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Cara Therapeutics"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Not Applicable"},{"orgOrder":0,"company":"Lupus Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Ianalumab","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Lupus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lupus Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Lupus Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Repirinast","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Algernon Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"WAL0921","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Walden Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Walden Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":3.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":3.5,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"CorMedix","sponsor":"RBC Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Taurolidine","moa":"","graph1":"Nephrology","graph2":"Phase IV","graph3":"CorMedix","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"CorMedix \/ RBC Capital Markets","highestDevelopmentStatusID":"11","companyTruncated":"CorMedix \/ RBC Capital Markets"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Mineralys Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lorundrostat","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Mineralys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mineralys Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mineralys Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Zigakibart","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Chinook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"INV-202","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Inversago Pharma","amount2":1.0800000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.0800000000000001,"dosageForm":"","sponsorNew":"Inversago Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"Inversago Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"Chinook Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Chinook Therapeutics","amount2":3.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":3.5,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Chinook Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Zenyaku Kogyo","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Rituximab","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Zenyaku Kogyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zenyaku Kogyo \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Zenyaku Kogyo \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"KYV-101","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Everest Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Everest Medicines"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imlifidase","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"KBP Biosciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"KBP Biosciences","amount2":1.3,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":1.3,"dosageForm":"Tablet","sponsorNew":"KBP Biosciences \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"KBP Biosciences \/ Novo Nordisk"},{"orgOrder":0,"company":"Omeros","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Narsoplimab","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ SLR Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ SLR Capital Partners"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Potassium Citrate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"12","companyTruncated":"Avanzanite Bioscience \/ Advicenne"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NKX019","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"United Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"United Therapeutics \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"United Therapeutics \/ United Therapeutics"},{"orgOrder":0,"company":"Genexine","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efepoetin Alfa","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genexine \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Genexine \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Ardelyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tenapanor","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Ardelyx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ardelyx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ardelyx \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Renal Autologous Cell Therapy","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProKidney \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Not Applicable"},{"orgOrder":0,"company":"One Biosciences","sponsor":"AP-HP","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Discovery","graph3":"One Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"One Biosciences \/ AP-HP","highestDevelopmentStatusID":"2","companyTruncated":"One Biosciences \/ AP-HP"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"SC291","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"2-hydroxypropyl-beta-cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ George Clinical","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Therapeutics, Inc \/ George Clinical"},{"orgOrder":0,"company":"Miromatrix Medical","sponsor":"United Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Miromatrix Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Miromatrix Medical \/ United Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Miromatrix Medical \/ United Therapeutics"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"SanReno Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"SanReno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SanReno Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"SanReno Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Milla Pharmaceuticals","sponsor":"Woodward Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Acetate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Milla Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Milla Pharmaceuticals \/ Woodward Pharma Services","highestDevelopmentStatusID":"12","companyTruncated":"Milla Pharmaceuticals \/ Woodward Pharma Services"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"University of Michigan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"WAL0921","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Walden Biosciences \/ University of Michigan","highestDevelopmentStatusID":"6","companyTruncated":"Walden Biosciences \/ University of Michigan"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Alpha Wave Global","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Alpha Wave Global","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Alpha Wave Global"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ilofotase Alfa","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Renalys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Tablet, Film Coated","sponsorNew":"Travere Therapeutics \/ Renalys Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Renalys Pharma"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Pharma \/ Not Applicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Deerfield Management","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Zegocractin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"CalciMedica \/ Deerfield Management","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Deerfield Management"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"DISC-0974","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ AbbVie Inc"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Kezar Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Kezar Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Kezar Life Sciences"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Cilastatin","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"University of Calgary","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ University of Calgary","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ University of Calgary"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"ZyVersa Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZyVersa Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Vadadustat","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"Akebia Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"I-Mab Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Finerenone","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Alebund Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"EOS789","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Alebund Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Chugai Pharmaceutical \/ Alebund Pharmaceuticals"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MTX652","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Mission Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zibotentan","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Zirconium Cyclosilicate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BI 690517","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Not Applicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sibeprenlimab","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ATA3219","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Calliditas Therapeutics AB \/ Everest Medicines","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Everest Medicines"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARO-CFB","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sirolimus","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Concept Medical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Concept Medical \/ Not Applicable"},{"orgOrder":0,"company":"Arch Biopartners","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"LSALT Peptide","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Arch Biopartners","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arch Biopartners \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arch Biopartners \/ Not Applicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Inaxaplin","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Equillium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Itolizumab","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equillium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Equillium \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":4.9000000000000004,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":4.9000000000000004,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Renalys Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Renalys Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Renalys Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Renalys Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Alpine Immune Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Povetacicept","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Alpine Immune Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alpine Immune Sciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Alpine Immune Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Iptacopan Hydrochloride","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"WAL0921","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Walden Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Walden Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Averoa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Averoa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Averoa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Averoa \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ARO-CFB","moa":"","graph1":"Nephrology","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zegocractin","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CalciMedica \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CalciMedica \/ Not Applicable"},{"orgOrder":0,"company":"Travere Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sparsentan","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Travere Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Travere Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"12","companyTruncated":"Travere Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AUR200","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Everest Medicines \/ Calliditas Therapeutics AB","highestDevelopmentStatusID":"12","companyTruncated":"Everest Medicines \/ Calliditas Therapeutics AB"},{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Voclosporin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aurinia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurinia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"Primula Group","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"WAL0921","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Walden Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Walden Biosciences \/ Primula Group","highestDevelopmentStatusID":"6","companyTruncated":"Walden Biosciences \/ Primula Group"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sevelamer Hydrochloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.8,"dosageForm":"Infusion","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Biogen"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"HI-Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"NKX019","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"ProKidney","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Rilparencel","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"ProKidney","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"ProKidney \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"ProKidney \/ Jefferies"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"HI-Bio","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Felzartamab","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"HI-Bio","amount2":1.8,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":1.8,"dosageForm":"","sponsorNew":"HI-Bio \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"HI-Bio \/ Biogen"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Phosphorylated Hexaacyl Disaccharide","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Polystyrene Sulfonate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Atrasentan","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Calliditas Therapeutics AB \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Calliditas Therapeutics AB \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ocedurenone","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Potassium Chloride","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RVL-HV02","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Revelation Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Revelation Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Revelation Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"BioCity Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"SC0062","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"BioCity Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"BioCity Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioCity Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tiopronin","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"12","companyTruncated":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited"}]
Find Nephrology Clinical Drug Pipeline Developments & Deals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
